Skip to content
No results
  • Home
  • News
  • Press Releases
  • Business
  • Technology
  • Research
  • Regulatory
  • Events and Conferences
  • About Us
  • Contact Us
  • About Us
  • Contact Us
The Pharma Data
  • News
  • Press Releases
  • Business
  • Technology
  • Research
  • Regulatory
  • Events and Conferences
The Pharma Data
  • ResearchPress Releases

Menarini Showcases ORSERDU® Advances at SABCS 2024 for ER+, HER2- mBC

  • The Pharma Data
  • November 26, 2024

Menarini Presents Data at SABCS 2024 Showcasing ORSERDU®’s Potential in ER+/HER2- Metastatic Breast Cancer The Menarini Group and its subsidiary, Stemline Therapeutics, are set to unveil new and expanded findings…

Read MoreMenarini Showcases ORSERDU® Advances at SABCS 2024 for ER+, HER2- mBC
  • Research

Exact Sciences Showcases Oncotype DX® and Genomic Research at SABCS 2024

  • The Pharma Data
  • November 26, 2024

Exact Sciences Highlights the Impact of Oncotype DX® and Genomic Insights at SABCS 2024 Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, will present a robust array of…

Read MoreExact Sciences Showcases Oncotype DX® and Genomic Research at SABCS 2024
  • Press Releases

Bicycle Therapeutics to Present Zelenectide Pevedotin Data at SABCS 2024

  • The Pharma Data
  • November 26, 2024

Bicycle Therapeutics to Present Key Zelenectide Pevedotin Data at SABCS 2024 and Share Program Updates Bicycle Therapeutics plc (NASDAQ: BCYC), a company at the forefront of developing a novel therapeutic…

Read MoreBicycle Therapeutics to Present Zelenectide Pevedotin Data at SABCS 2024
  • Business

Enanta Pharmaceuticals Announces Fiscal Q4 and Full-Year 2024 Financial Results

  • The Pharma Data
  • November 26, 2024

Enanta Pharmaceuticals Delivers Key Updates on Virology and Immunology Programs While Reporting Fiscal Year 2024 Results Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company specializing in small molecule drugs…

Read MoreEnanta Pharmaceuticals Announces Fiscal Q4 and Full-Year 2024 Financial Results
  • Press Releases

Global Leaders Unite with Jeddah Commitments to Combat Antimicrobial Resistance

  • The Pharma Data
  • November 25, 2024

The Quadripartite organizations – the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organisation for…

Read MoreGlobal Leaders Unite with Jeddah Commitments to Combat Antimicrobial Resistance
  • News

Lebanon: A Conflict Devastating Health Care Systems

  • The Pharma Data
  • November 25, 2024

Since October 7, 2023, Lebanon has experienced an alarming escalation in attacks on health care, with nearly half of these assaults proving fatal to health workers or patients. As of…

Read MoreLebanon: A Conflict Devastating Health Care Systems
  • Press Releases

Halozyme Withdraws Acquisition Proposal for Evotec Amid Lack of Engagement

  • The Pharma Data
  • November 25, 2024

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) at €11.00 per share in cash, representing a fully diluted equity value…

Read MoreHalozyme Withdraws Acquisition Proposal for Evotec Amid Lack of Engagement
  • Press Releases

Can Cancer Be Treated by Activating the Body’s Defense System?

  • The Pharma Data
  • November 25, 2024

Cancer treatments are evolving, with increasing focus on using the body’s immune defenses to combat the disease. Reetta Virtakoivu, Senior Scientist at Orion, explains how immunotherapy works and why it…

Read MoreCan Cancer Be Treated by Activating the Body’s Defense System?
  • Regulatory

FDA Approves Attruby™ (acoramidis) to Reduce Cardiovascular Risks in ATTR-CM Patients

  • The Pharma Data
  • November 25, 2024

BridgeBio Pharma, Inc. announced the FDA approval of Attruby™ (acoramidis), an oral stabilizer of transthyretin (TTR), for adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This treatment aims to reduce cardiovascular death…

Read MoreFDA Approves Attruby™ (acoramidis) to Reduce Cardiovascular Risks in ATTR-CM Patients
  • Press Releases

Versant Ventures Launches Pep2Tango Therapeutics Inc

  • The Pharma Data
  • November 22, 2024

Versant Ventures has announced the launch of Pep2Tango Therapeutics Inc., a new startup focused on next-generation weight loss treatments. The company will use funds from a significant, undisclosed investment round…

Read MoreVersant Ventures Launches Pep2Tango Therapeutics Inc
  • News

Population Health Research Institute Celebrates 25 Years of Advancing Global Health Research and Innovation

  • The Pharma Data
  • November 22, 2024

Population Health Research Institute (PHRI), a joint initiative of McMaster University and Hamilton Health Sciences, is celebrating its 25th anniversary as a global leader in health research. Over the past…

Read MorePopulation Health Research Institute Celebrates 25 Years of Advancing Global Health Research and Innovation
  • Business

ReAlta Life Sciences Appoints Lewis T. Williams, M.D., Ph.D. as Chairman

  • The Pharma Data
  • November 22, 2024

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on rebalancing the inflammatory response to treat rare and acute inflammatory diseases, has announced the appointment of…

Read MoreReAlta Life Sciences Appoints Lewis T. Williams, M.D., Ph.D. as Chairman
PrevNext

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • EmeraNova™ Strengthens Innovation Leadership with Launch of New Accelerator ProgramNovember 5, 2026
  • Global Healthy Living Foundation Highlights Advances in Myositis and Polymyalgia Rheumatica Research at ACR Convergence 2026November 5, 2026
  • Polaris Rx Chosen by Bristol Myers Squibb to Distribute ZENBEXUS™, the First FDA-Approved CELMoD Treatment for Multiple MyelomaNovember 5, 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.